Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.
(2016) Journal of Alzheimer’s Disease — Vol. 49, n° 2, p. 271-276 (2016)
Files
document.pdf
Restricted Access - Adobe PDF
- 280.25 KB
Details
- Authors
- Abstract
- We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.
- Affiliations
Citations
Pierrot, N., Lhommel, R., Quenon, L., Hanseeuw, B., Dricot, L., Sindic, C., Maloteaux, J.-M., Octave, J.-N., & Ivanoiu, A. (2016). Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer’s Disease. Journal of Alzheimer’s Disease, 49(2), 271-276. https://doi.org/10.3233/JAD-150405 (Original work published 2016)